News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gemin X Biotechnologies Inc. Presents Positive Preclinical Data of GX15-070 in Infant ALL at American Association for Cancer Research Meeting



4/18/2007 12:59:44 PM

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Gemin X today announced the presentation of positive preclinical data from a study of its lead compound, GX15-070 (obatoclax), in infant acute lymphoblastic leukemia (ALL). The study was discussed in an oral presentation at the Annual Meeting of the American Association for Cancer Research (AACR). According to the study, GX15-070 demonstrated potent single agent activity against ALL blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES